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Summary
The translation of university research into commercial success—technology transfer—
is a well-researched, and well-reviewed, area. Indeed, the development of an evidence 
base on technology transfer has benefitted from a succession of high-profile, often 
Government-sponsored, reviews on how to improve collaboration between universities 
and business, and increase the commercialisation of academic research. Such efforts 
are to be commended, but successes in identifying the challenges associated with 
technology transfer have yet to be matched by progress in tackling the underlying 
problems. Instead, technology transfer has been dominated by an ongoing ‘review 
culture’ and an ‘implementation deficit’.
Our inquiry appears, however, to have helped refocus the Government’s attention 
on technology transfer and the need for action. The Industrial Strategy Green Paper 
describes the Government’s aim to “do more to commercialise our world leading 
science base”. This is supported by additional funding, announced during the course of 
our inquiry, including £120 million, over the next four years, to “incentivise university 
collaboration in tech transfer” as well as the establishment of a separate ‘Industrial 
Strategy Challenge Fund’ to address “Britain’s historic weakness on commercialisation”.
We welcome the Government’s renewed emphasis on technology transfer but remain 
concerned that its previous efforts have disproportionately focused on the ‘supply’ of 
research by universities, rather than on the level of ‘demand’ from businesses. Without 
a healthy commercial demand for R&D, the scope for universities to engage more in 
technology transfer is limited. Progress on this, however, is disappointing—the overall 
R&D intensity of the UK business sector continues to be low compared to other OECD 
countries. The Industrial Strategy, combined with the Government’s forthcoming 
reviews of R&D tax credits, the Small Business Research Initiative, and the VAT system, 
all present valuable opportunities for the Government to refocus its efforts on raising 
demand for university research, and creating the conditions that are conducive to 
businesses investing more in R&D.
The Government has also announced that it intends to commission research to examine 
“different institutions’ principles and practices on commercialisation of intellectual 
property (IP)”. The valuation of IP, and the amount of equity taken in spin out companies, 
are contentious issues. Some evidence indicates that technology transfer offices are 
prioritising short-term revenue generation and overvaluing IP, whereas others maintain 
that this is not common practice. Technology transfer offices are often in the middle 
of complex IP negotiations and are tasked with balancing competing priorities, with 
varying degrees of support. The Government’s forthcoming research should therefore 
examine what skills are needed to successfully value IP, and broker negotiations, as well 
as how these skills may vary by sector.
We were surprised to find that engagement between Local Enterprise Partnerships 
(LEPs) and universities is patchy. Despite having a mandate, and funding, to promote 
local innovation, LEPs are currently lacking any firm obligation, or support, to connect 
local businesses and higher education institutions. In contrast, the four pilot ‘University 
Enterprise Zones’, established with the explicit aim of increasing interaction between 
universities and business, are notably missing from the Industrial Strategy Green 
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Paper and face uncertain future funding. The Government should use the opportunity 
presented by the Industrial Strategy to oblige all LEPs to work with their local universities, 
or else reassign a proportion of their funding sufficient to roll-out a national university 
enterprise zones programme.
Finally, the Government must be careful not to damage the UK’s pre-eminent position 
in academic research in pursuit of ever-greater commercialisation. The vast majority of 
innovations do not begin as discoveries in academic research and the Government must 
be alert to, and address the needs of, the UK’s broader innovation landscape.
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1 Introduction
1. Technology transfer describes the movement of knowledge, or technology, from 
one organisation to another. In higher education institutions, it is the process of 
commercialising university-owned ‘intellectual property’ (IP), namely “creations of the 
mind, such as inventions, literary [ … ] works and designs”1 that can be protected through 
patents, trademarks and copyright. Commercialisation may be achieved through the 
licencing of IP to existing companies or through setting up new, ‘spin-out’ companies. To 
facilitate this transaction, many universities have established ‘technology transfer offices’ 
(TTOs). Though the exact remit of a TTO varies between universities, they are generally 
responsible for identifying, protecting and transferring knowledge created in universities 
“out to business where it can be developed into products and services that benefit society”.2
2. Despite being in widespread usage, the term technology transfer has been criticised 
for implying that innovation is a linear process that begins in universities and ends with 
a commercialised product. Evidence heard by our predecessor Committee during its 
Bridging the Valley of Death inquiry in 2013 highlighted that very few innovations start as 
discoveries in academic research.3 The Higher Education Funding Council for England 
(HEFCE) told our predecessors that:
The vast majority of new technologies in the world that become 
commercially adopted will be devised and developed in the business world, 
by entrepreneurs, technology consultants, large and small businesses and in 
supply chains (albeit, we believe, infused and informed by university ideas 
and human capital development) [ … ] we estimate that only 19% of patent 
application filings from [the] UK [originate in] universities.4
3. While technology transfer is likely to be a more complex, interactive, and iterative 
process than the term implies, successive Governments and universities have increasingly 
focused their efforts on improving the translation of university research into commercial 
success. Three months after launching our inquiry, for example, in October 2016, the 
Chancellor announced funding of:
£120 million [over the next four years] to incentivise university collaboration 
in tech transfer and in engaging with business, helping transform research 
at universities and institutions into viable business ventures.5
The following month the Government announced the establishment of the ‘Industrial 
Strategy Challenge Fund’ to “address Britain’s historic weakness on commercialisation 
and [turn] our world-leading research into long-term success”.6 While further details are 
1 World Intellectual Property Organization, What is Intellectual Property?
2 Brady, C et al, UK University Technology Transfer: behind the headlines. A note from the UK’s leading university 
technology transfer professionals, April 2015
3 Science and Technology Committee, Eighth Report of Session 2012–13, Bridging the valley of death: improving 
the commercialisation of research, HC 348
4 Science and Technology Committee, Eighth Report of Session 2012–13, Bridging the valley of death: improving 
the commercialisation of research, HC 348, Ev 140, para 27
5 “£220 million for cutting-edge new technology”, HM Treasury and Department for Business, Energy & Industrial 
Strategy news story, 1 October 2016
6 CBI annual conference 2016: Prime Minister’s speech, 21 November 2016
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expected shortly, the Government has stated that it will “consult on how the fund can 
best support emerging fields [ … ] and other areas where the UK has a proven scientific 
strength and there is a significant economic opportunity for commercialisation”.7
4. In addition to providing funding for technology transfer, the Government is also 
in the process of restructuring the governance of research and innovation through the 
Higher Education and Research Bill and the establishment of UK Research and Innovation 
(UKRI—a move we examined in detail in an earlier report Setting up UK Research & 
Innovation).8 By establishing UKRI—which comprises the seven research councils, 
Innovate UK and Research England—the Government anticipates that businesses will be 
given “a much clearer understanding of the opportunities” available from the “intellectual 
property [ … ] being generated [ … ] in our research community”.9 Furthermore, it is 
hoped that “proximity and cross-fertilisation between the SMEs that use Innovate UK’s 
services [and] the academic community [ … ] will stimulate more commercialisation”.10
5. Over the last 15 years, there has also been a succession of high-profile, often 
Government-sponsored, reviews examining the relationships between business and 
universities. Dame Ann Dowling’s report on Business-University Research Collaborations, 
published in July 2015, identified 12 such reviews, including her own.11 The sheer volume of 
work on this area, however, does not appear to have swept away the barriers to technology 
transfer. This became particularly apparent early in 2016 when we held a short inquiry to 
examine research and innovation in graphene. That inquiry raised general issues about 
the role of universities in the commercialisation of research, many of which went beyond 
the specific case of graphene (see Annex). As the Nobel Prize-winning physicist, Sir Andre 
Geim, explained:
Historically, universities have two major remits: one is education and the 
other is bringing basic knowledge [ … ] Now we have a new situation where 
universities are going from asking questions to being held responsible for 
commercialisation, which has never previously been a remit of universities. 
There is nothing wrong with that. As universities we are publicly funded 
organisations, and of course it is Government and the taxpayer who own 
the remit of the universities, but because it is a recent situation this remit is 
neither adequately funded nor does it even have a legal basis.12
Our inquiry
6. We decided to look more closely at what has been described as the ‘third function’ or 
‘third stream’ of universities and, in July 2016, we launched a separate inquiry to examine 
how higher education institutions manage intellectual property and technology transfer. 
Written submissions were sought addressing the following points:
7 “PM announces major research boost to make Britain the go-to place for innovators and investors”, Prime 
Minister’s Office and Department for Business, Energy & Industrial Strategy Press release, 21 November 2016
8 Science and Technology Committee, Eighth Report of Session 2016–17, Setting up UK Research & Innovation, HC 
671
9 Q289
10 ibid
11 The Dowling Review of Business-University Research Collaborations, July 2015, p11
12 Oral evidence taken on 26 April 2016 HC (2016–17) 960, Q69 [Sir Andre Geim]
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• How the respective roles of universities and TTOs in commercialising research 
have developed over the last decade;
• How well universities and TTOs balance objectives of protecting IP and 
encouraging public-benefit research, and whether TTOs’ and universities’ IP 
strategies effectively deliver such objectives in practice;
• Any scope for individual universities/TTOs to adopt particular good practices 
and IP strategies from others:
• Whether funding arrangements for research commercialisation by TTOs are 
adequate and whether they facilitate an appropriate balance of objectives and an 
appropriate balance between short-term and longer-term aims;
• Whether SMEs and larger businesses are both given an equitable access to 
commercialisation opportunities;
• What measures universities, business leaders and Government should take to 
assist the commercialisation process, and to reach a common understanding of 
how the different stakeholders involved can engage in the process.
7. We received 39 submissions and took oral evidence from 19 witnesses including:
• professionals working in university technology transfer offices;
• entrepreneurs;
• businesses and trade associations;
• legal and finance professionals;
• the Royal Academy of Engineering;
• officials from the Department of Business, Energy and Industrial Strategy and 
Intellectual Property Office;
• the Government, represented by Jo Johnson MP, Minister of State for Universities, 
Science, Research and Innovation.
We would like to thank everyone who contributed to the inquiry.
8. We recognise that there has been a strong ‘review culture’ in the field of technology 
transfer and business-university collaboration. We welcome, and broadly support, the 
recommendations made in Dame Ann Dowling’s comprehensive review of Business-
University Research Collaborations and do not seek to rehearse all of those recommendations 
in this report. Rather, in light of the developing Industrial Strategy, and the establishment 
of the Industrial Strategy Challenge Fund, we have instead identified three aspects of the 
problem that need to be prioritised, and urgently addressed, through the new Industrial 
Strategy. Chapter 2 therefore considers how business demand for technology transfer might 
be increased while Chapter 3 focuses on the geographical context in which technology 
transfer occurs. Chapter 4 looks at funding and support for commercialising research, 
with conclusions drawn in Chapter 5.
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2 Stimulating demand for technology 
transfer
9. During the course of our inquiry into graphene, we heard that both large companies 
and SMEs were keen to work with the National Graphene Institute (NGI) and develop 
commercially viable applications of the material (see Annex). Sir Andre Geim from the 
University of Manchester recalled that:
Five years ago, I got an inquiry every day from companies about what they 
could do with graphene and whether we could help. Fortunately, now all 
those inquiries end up at the NGI. I heard that there are 900 every year, so 
there are about four inquiries per day from companies.13
Contributors to our technology transfer inquiry stressed, however, that this level of demand 
from business to collaborate with a university was not typical. This Chapter considers 
current levels of investment in R&D by UK business and how this may be increased.
Research intensity of British business
10. Cambridge Enterprise (the TTO of the University of Cambridge) identified a 
general “lack of demand from businesses both small and large for commercialisation 
opportunities”.14 This, they told us, reflected the findings of the “Lambert Review of 
Business–University Collaboration”, published in 2003, which concluded that the:
biggest challenge identified in this Review lies on the demand side. 
Compared with other countries, British business is not research intensive, 
and its record of investment in R&D in recent years has been unimpressive. 
UK business research is concentrated in a narrow range of industrial 
sectors, and in a small number of large companies. All this helps to explain 
the productivity gap between the UK and other comparable economies.15
11. According to Sir Richard Lambert’s review, the key question was “how to raise the 
overall level of demand by business for research from all sources” and thereby increase the 
scope for technology transfer.16 This point was reiterated 10 years later by our predecessor 
Committee in its 2013 report, Bridging the Valley of Death, which recommended that 
“the Government’s objective should be to create a commercial demand for university 
engagement to which they are already primed to respond”.17 Cambridge Enterprise 
noted, however, that the Government’s response to date had predominately focused on 
universities and the supply side of the equation. It stressed that “until the demand side is 
addressed the commercialisation challenge will remain for universities”.18
13 Oral evidence taken on 26 April 2016 HC (2016–17) 960, Q69 [Sir Andre Geim]
14 Cambridge Enterprise (MIP0029) para 48
15 Cambridge Enterprise (MIP0029) para 49.1
16 HM Treasury, The Lambert Review of Business-University Collaboration, December 2003, p3
17 Science and Technology Committee, Eighth Report of Session 2012–13, Bridging the valley of death: improving 
the commercialisation of research, HC 348, para 127
18 Cambridge Enterprise (MIP0029) para 52
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12. Dr Tony Raven from Cambridge Enterprise told us that the research intensity of 
British business had changed for the better in the intervening period but “not radically”.19 
Expenditure on R&D by UK businesses reached £20.9 billion in 2015, the highest level 
since records began.20 Yet, when placed in an international context, the “R&D intensity of 
the [UK] business sector continues to be low” compared to other OECD countries.21 OECD 
figures from 2015 showed that while UK business was spending 1.12% of GDP on R&D, 
the OECD average was 1.65%, with Germany spending 1.95% and South Korea 3.28%.22 
Measures of innovation output—namely the proportion of companies introducing new, 
or significantly improved, goods and services—also showed a decline from 24% to 18% 
between 2008 and 2012 before rising to 19% in 2015.23
13. Dr Claire Brady from the University of Edinburgh’s technology transfer office, 
however, was careful to distinguish between sectors, rather than treat ‘business’ as 
a homogenous group. According to Dr Brady, “demand depends a lot on company 
pipelines and company need” and was “different across sectors and across different sizes 
of companies”.24 She held up the pharmaceutical industry, and its ongoing collaborations 
with universities, as a positive case in point.25 Professor Trevor McMillan, who recently 
authored a report on ‘Good practice in Technology Transfer’ for HEFCE, also identified 
‘sectoral variations’ in technology transfer as something that required more thought and 
understanding by TTOs.26
14. Jo Johnson MP, the Minister responsible for universities, science, research and 
innovation, was clear that the UK had “a strong innovation ecosystem”, noting that the 
country was ranked “very high on the global innovation scorecard” and that “pound per 
pound [the UK does] very well in terms of exploiting opportunities for innovation”.27 He 
agreed, however, that the UK did “invest less in terms of what our business community 
is doing” and that this had “been a consistent feature of our industrial landscape relative 
to other developed economies”.28 The Government’s Industrial Strategy Green Paper 
subsequently announced that it would be exploring how the additional £4.7 billion of 
research funding by 2020–21 could be best used, alongside the tax environment for R&D, 
“to drive up the level of private investment in science, research and innovation across the 
economy”.29
19 Q17
20 Office for National Statistics , Statistical bulletin: Business enterprise research and development, UK: 2015, 
November 2016
21 OECD Science, Technology and Industry Scoreboard 2015, United Kingdom Highlights, October 2015
22 OECD, Main Science and Technology Indicators, BERD as a percentage of GDP
23 Department for Business, Energy and Industrial Strategy, The UK Innovation Survey 2015 Main Report, 
Innovation Analysis, July 2016, p 11; see also Barnett, A et al, The UK productivity puzzle, Bank of England 
Quarterly Bulletin, 2014 Q2, p 122
24 Q18 [Dr Brady]
25 Q18 [Dr Brady]
26 Professor Trevor McMillan (MIP0005)
27 Q319
28 Q281
29 HM Government, Building Our Industrial Strategy, Green Paper, January 2017, p 29
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15. Successful technology transfer does not begin and end with universities; business 
also has a vital part to play. Yet, compared to our OECD counterparts, the research 
intensity of UK business is low. Without a healthy commercial demand for R&D, 
the scope for universities to engage more in technology transfer will be limited. 
Responsibility for remedying this problem does not rest solely with the Government, 
but it should be leading the way by creating conditions that are conducive to businesses 
investing more in R&D. To date, however, the Government’s efforts to increase 
technology transfer have been disproportionately targeted at the university, rather 
than business, sector.
16. The lack of progress forces us to reiterate the recommendation made in our 2013 
report, namely for the Government to “create a commercial demand for university 
engagement to which they are already primed to respond”. Facilitating greater 
investment in UK R&D by British business should be a key goal of the Government’s 
Industrial Strategy.
17. The remainder of this chapter considers how business demand for R&D could be 
further encouraged and incentivised.
R&D Tax Credits
18. Our witnesses identified R&D tax credits as an important tool that could “stimulate 
and incentivise spending on R&D”.30 Established in 2000, they allow companies to reduce 
their tax bill or claim payable cash credits for a proportion of their R&D expenditure. 
Claims have grown 35 fold since their introduction: the Government highlighted that 
businesses “benefit from tax credits of £1.75 billion in 2013–14 compared with £70 million 
in 2000–01”31 and had risen to £2.45 billion in 2015–16.32 Whilst welcoming R&D tax 
credits, witnesses stressed that the both the eligibility criteria and claims process were 
complex.
19. Dr Toby Basey-Fisher from Eva Diagnostics described how his company “had to 
move to a specialist [accountancy] firm just to get the R&D tax credits” since his original 
“accountancy firm did not understand it”.33 Part of the challenge, according to Dr Phil 
Clare from Praxis Unico, was that R&D tax credits were:
inevitably a complicated accounting activity that requires detailed 
assessment on whether something fits in the box or not [ … ] If, for example, 
you were able to say that any R&D spend in a university was eligible for an 
R&D tax credit, it would be very clear, simple and easy for us to promote 
and explain to our partners that if they spend money with us they get a 
benefit.34
20. Innovate UK also stressed that “tax credits do not encourage R&D specifically in 
collaboration with universities”. They suggested addressing this through “the development 
of separate schemes focussing on business-university collaboration or investments 
30 Q78 [Dr Clare]; see also Innovate UK (MIP0006) para 33; Q141
31 Department for Business, Energy and Industrial Strategy (MIP0011) para 28
32 Q281
33 Q78 [Dr Basey-Fisher]
34 Q78 [Dr Clare]
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in companies based on UK university IP”.35 There are currently two R&D tax credits 
schemes; one for SMEs and the other for large companies. Felicity Burch from the CBI 
recommended “supercharging small companies’ R and D tax credits, to make them even 
more of a boost to companies’ cash flow” and “enabling companies to access that money 
on a quarterly rather than an annual basis [to] give them cash back a little more quickly”.36 
We made a similar point in our Science Budget report in 2015.37 The Minister, however, 
described the R&D tax credit system as “generous and increasingly popular”, though 
noted that the Chancellor had announced at the 2016 Autumn Statement “a review of the 
R&D tax environment for business to look at whether it was as competitive as it needs to 
be”.38
21. We recommend that the Government’s review of R&D tax credits should carefully 
consider how the qualification and claims process for both the SME, and large company, 
schemes could be simplified so that they explicitly support business R&D in collaboration 
with higher education institutions.
Small business research initiative
22. A review of the Small Business Research Initiative (SBRI), led by the Cambridge 
entrepreneur Dr David Connell, was announced by the Government at the same time as 
the R&D tax credits review. According to the Minister, the SBRI helps “small businesses 
take advantage of procurement contracts that Government are offering so that they can 
offer their services in an innovative way”.39 The SBRI is a:
two stage, contract-based programme to fund the development of innovative 
technology solutions to meet government needs—either for departments’ 
own requirements or to meet policy challenges. Phase 1 contacts are 
typically worth £50–100,000 and Phase 2 £250,000 to £1 million. Project 
costs are 100% funded.40
23. Commenting on the review, the Prime Minister was enthusiastic about the 
Government’s capacity to “step up to help drive innovative procurement, particularly 
from small businesses”.41 She also highlighted how effective this approach had been in the 
United States, under its Small Business Innovation Research (SBIR) initiative. Unlike the 
UK, the SBIR in the United States has a sister programme—Small Business Technology 
Transfer (STTR)—which has a requirement for “the small business to formally collaborate 
with a research institution”.42
24. The Dowling Review similarly singled out the UK’s SBRI scheme as an important 
mechanism for encouraging collaboration and engaging small businesses. Dame Ann 
Dowling told us that the SBRI represented a “huge opportunity to use Government 
35 Innovate UK (MIP0006) para 33
36 Q113 [Felicity Burch]
37 Science and Technology Committee, First Report of Session 2015–16, The Science Budget, HC 340, para 80
38 Q281
39 Q282
40 David Connell, Review of Small Business Research Initiative (SBRI), Innovate UK blog, 16 December 2016
41 CBI annual conference 2016: Prime Minister’s speech, 21 November 2016
42 “About STTR”, last accessed on 1 March 2017 at http://www.sbir.gov/about/about-sttr
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procurement to help SMEs” and “join up academics with small companies around a new 
product”.43 To date, however, the UK’s scheme has lagged behind its US counterpart. In 
Budget 2013, the Government announced that it would:
substantially expand SBRI among key departments so that the value of 
contracts through this route increases from £40 million in 2012–13 to over 
£100 million in 2013–14 and over £200 million in 2014–15.44
But, according to the Dowling Review, the SBRI had:
not yet met the expectations placed on it by government or the research 
community and is widely perceived to be less successful than the US Small 
Business Innovation Research (SBIR) model. In 2013—14, £78.5 million of 
contracts were awarded via the SBRI mechanism, falling short of the target 
of £100 million.45
25. In December 2016, David Connell confirmed that the 2014–15 target of £200 million 
had also not been met.46 Figures given to us by the Minister indicated that the value of 
contracts awarded had, in fact, decreased. According to the Minister, the SBRI “currently 
provides around £63 million of contracts a year to businesses”, approximately £15.5 
million less than was awarded in 2013–14.47 Dr Connell also noted that there were “many 
[Government] departments that don’t use SBRI at all”.48
26. Government procurement via the Small Business Research Initiative (SBRI) is 
a valuable means through which to stimulate innovation, especially among SMEs. 
The SBRI, however, has consistently underperformed against the Government’s own 
targets and has yet to reach its full potential. We recommend that the current review of 
the SBRI consider what mechanisms could be put in place to encourage small businesses 
to collaborate with research institutions as part of the SBRI scheme.
Online brokerage platforms
27. Some SMEs told us during our graphene inquiry that they found it difficult to access 
graphene commercialisation opportunities and engage with the National Graphene 
Institute, though other SMEs had different experiences (see Annex).49 In our technology 
transfer inquiry, we heard that both SMEs and larger businesses were generally given 
equitable access to commercialisation opportunities, but that larger businesses tended to 
be more readily able to take advantage of those opportunities. As the Academy of Medical 
Sciences explained:
SMEs are often focused on managing the immediate pressures of day-to-
day operations, which means they may struggle to find the spare capacity to 
engage with universities to investigate potential licensing and collaborative 
opportunities.50
43 Q250
44 HM Treasury, Budget 2013, March 2013, HC 1033, para 1.146
45 The Dowling Review of Business-University Research Collaborations, July 2015, para 168
46 David Connell, Review of Small Business Research Initiative (SBRI), Innovate UK blog, 16 December 2016
47 Q308
48 David Connell, Review of Small Business Research Initiative (SBRI), Innovate UK blog, 16 December 2016
49 Oral evidence taken on 26 April 2016 HC (2016–17) 960, Q20 [Dr Cox]
50 Academy of Medical Sciences (MIP0012) para 6.1
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Similarly, Imperial Innovations suggested that larger organisations were “more likely 
to employ staff whose role is to discover new technologies and have more resources to 
engage”.51 Navigating the plethora of organisations involved in technology transfer was 
also singled out as a barrier to collaborating with universities for SMEs. The Government 
recognised that it was hard for:
SMEs with limited resources to navigate so many institutions and ideas 
and it is hard for universities to engage a myriad of smaller commercial 
partners.52
28. To make it easier for all businesses to identify potential academic partners, and 
understand where academic capabilities lie, the National Centre for Universities and 
Business (NCUB)53 worked with the Higher Education Funding Council for England 
(HEFCE), Innovate UK and the research councils to develop an ‘online brokerage 
platform’. Dr Rosa Fernández from the NCUB explained that the system, called ‘Konfer’, 
helped to identify potential research partners and was a “match.com-type” of platform:
Konfer rarely will give you a one to one [match]. We are normally trying to 
describe Konfer as saying that it will give one, two or three potential dates, 
but you still have to go to the date and find out whether you want to go with 
one another. It is unlikely at this stage that Konfer will give you the person 
you will marry; it will give you a few possible candidates.54
29. Universities UK thought that Konfer would “help make collaboration opportunities 
more visible to businesses of all sizes”.55 Knowledge of the platform—the pilot version of 
which was rolled out in 2016—was, however, patchy among some of our witnesses. Dr 
Will West from the BioIndustry Association told us that “very few people in industry 
know about [brokerage platforms]”, and that he had first heard about Konfer following 
our evidence session with the NCUB.56
30. Others questioned whether an online brokerage platform alone was sufficient to bring 
businesses and academics together. According to IN-PART (a business aimed at building 
university-industry collaborations):
most R&D companies do not have a dedicated technology scouting or open 
innovation team going out looking for opportunities. This means people 
from that company are very unlikely to go to a university website or passive 
platform to look at what they have to offer. Ultimately this means that direct 
approaches are required.57
Many witnesses described identifying potential collaboration partners as a “contact sport” 
that relied on networking and face-to-face interactions.58 What was needed, according to 
Professor Trevor McMillan from Keele University, was:
51 Imperial Innovations Group plc (MIP0020) para 8.1
52 Department for Business, Energy and Industrial Strategy (MIP0011) para 59
53 An independent, not for profit body, funding by the Research Councils and Innovate UK.
54 Q90
55 Universities UK (MIP0016) para 14
56 Q154 [Dr West]
57 IN-PART (MIP0032) para 4.5; see also The Dowling Review of Business-University Research Collaborations, July 
2015, para 67
58 see Q262, Q268; Q134; Q70 [Dr Clare]; Q18; Q13
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people on a daily basis wandering around, talking to the academics, getting 
them into the right mindset and then picking up on the ideas and gems 
when they appear.59
31. We welcome the development of ‘Konfer’ as a straightforward way for businesses 
to identify potential academic collaborators. Algorithms alone, however, will not 
produce productive collaborations: potential ‘matches’ will need to be nurtured 
through supportive human interventions. We recommend that the Government works 
with the National Centre for Universities and Business to publicise the Konfer platform. 
A business engagement team should also be established alongside Konfer to work with 
businesses and help develop the potential partnerships identified by the platform.
VAT rules
32. HEFCE’s 2014–15 Higher Education–Business and Community Interaction Survey 
indicated that 9% of university revenue from licensing IP to businesses came from SMEs 
(£13.8m out of a total IP revenue of £155m). Income from universities renting out their 
facilities to business, however, was more substantial, especially from SMEs, who accounted 
for 31% of the total income (£59m out of a total income of £191m).
33. Some witnesses suggested that further collaboration between businesses and 
universities was being held back by current VAT rules on income from academic buildings. 
Praxis Unico, the professional association for technology transfer, stated that “VAT issues” 
were constraining collaboration and that “VAT on academic buildings should be changed 
so that businesses can co-locate with universities without causing tax challenges”.60 As the 
Dowling Review explained:
The construction of publicly-funded or charity research institutes is eligible 
for zero-rate VAT on account of it being considered a Relevant Charitable 
Purpose. Research institutes which are publicly funded can therefore opt 
not to pay VAT. If they do so, the amount of commercial activity on their 
premises cannot exceed 5%, and this ‘commercial activity’ includes research 
collaboration with industry.61
34. In our recent inquiry Leaving the EU: implications and opportunities for science and 
research, we heard from UCL that “previous explanations for this state of affairs have been 
the requirements to comply with EU legislation”.62 In the 2016 Autumn Statement the 
Government reported that it had asked the Office for Tax Simplification (OTS) “to carry 
out reviews on aspects of the VAT system”.63 When we asked the Minister if he would be 
pushing the OTS to scrap VAT charges on buildings where academics and industry were 
working alongside one another, he was non-committal, stating that:
59 Q268
60 Praxis Unico (MIP0014) para 29; see also Institute of Cancer Research (MIP0018)
61 The Dowling Review of Business-University Research Collaborations, July 2015, para 78
62 Science and Technology Committee, Seventh Report of Session 2016–17, Leaving the EU: implications and 
opportunities for science and research, HC 502, para 48
63 HM Treasury, Autumn Statement 2016, Cm 9362, para 4.43
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We obviously want to ensure that we have a competitive R&D tax 
environment in this country that underpins the whole theme of the autumn 
statement, and I look forward to seeing the outcomes of the Treasury’s 
review.64
35. The UK’s exit from the European Union, combined with the Office for Tax 
Simplification’s reviews of the VAT system, present an opportunity to revise VAT rules 
on the income from academic buildings in a way that facilitates greater collaboration 
with business. We encourage the Office for Tax Simplification to examine the VAT rules 
on shared academic buildings with business as part of its current VAT review, and 
consider how they could be revised to enhance collaboration opportunities.
64 Q313
16  Managing intellectual property and technology transfer 
3 Regional and sectoral differences
36. The Business Secretary, the Rt Hon Greg Clark MP, has emphasised the importance 
of ‘place-based’ innovation in relation to the Industrial Strategy. In a speech in November 
2016 he explained that:
If there is a consistent theme, I think one of them is this: the connection 
between innovation and place [ … ] Scientific knowledge may be universal, 
but its development is local [ … ] What is needed in each place is different, 
and our strategy must reflect that.65
More recently, in its Industrial Strategy Green Paper, the Government has been clear that 
“regional disparities are now wider in the UK than in other western European nations” 
and that “the productivity gap within each region is greater than between regions”.66 We 
therefore examined if there was a ‘place-based’ element to managing IP and technology 
transfer, including whether a consideration of regional geographies has formed part of 
Government, business and university technology transfer strategies.
Sharing best practice
37. Professor Trevor McMillan’s report to HEFCE in 2016, University Knowledge 
Exchange (KE) Framework: good practice in technology transfer, was clear that technology 
transfer policies are sensitive to the local “entrepreneurial conditions beyond the 
university”.67 These include the local communications infrastructure, access to venture 
capital, and business and legal support. His report noted, however, that there had been 
“relatively little discussion in the UK about [the] spatial dimensions to technology 
transfer”.68 Professor McMillan also stressed that while a “university’s eco-system should 
influence its entrepreneurial policies”, so too should the university’s own “characteristics 
and circumstances”.69
38. The evidence we have received from universities, and from the Government, broadly 
supported these conclusions. Universities Scotland agreed that university technology 
transfer strategies should be developed “in the context of research strengths, sector 
needs and innovation ecosystems in which the institution operates”, thereby making it 
“important to avoid a one-size-fits-all approach” to technology transfer.70 HEFCE told us 
that there was still “scope for sharing good practices” without needing a single, ‘generic’ 
approach.71 We heard differing views, however, on how technology transfer offices should 
organise themselves to make this possible.
39. At present, the dominant UK model is for each university with significant technology 
transfer activity to have its own technology transfer office (TTO). Recognising that each 
TTO is differently staffed and resourced, Dr Daniel Nelki from the Wellcome Trust 
65 “A place for innovation”, Speech delivered at the Innovate 2016 Conference in Manchester by Rt Hon Greg Clark 
MP, 3 November 2016
66 HM Government, Building Our Industrial Strategy, Green Paper, January 2017 p 14–15
67 University Knowledge Exchange (KE) Framework: good practice in technology transfer. Report to the UK higher 
education sector and HEFCE by the McMillan group, Sept 2016, para 6
68 ibid para 51
69 Ibid para 11
70 Universities Scotland (MIP0030)
71 Higher Education Funding Council for England (HEFCE) (MIP0007)
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suggested that some smaller universities did not have “the throughput or capability to 
deal with technologies [or the] requisite expertise and advice that should be available”.72 
He believed that establishing “some regional centres” to advise “local institutions” could 
prove “hugely advantageous”.73
The SETsquared Partnership was repeatedly highlighted in our evidence as an example 
of technology transfer resources being effectively pooled across a wide geographical 
area.74 SETsquared is a collaboration between the universities of Bath, Bristol, Exeter, 
Southampton and Surrey “on research commercialisation, student enterprise and business 
incubation”.75 Nick Sturge from the University of Bristol explained that while SETsquared 
is comprised of “five independent institutions with their own agendas and their own 
relationships with the local environment” the collaboration benefitted “from a common 
brand” and worked by “aligning the common bits of different agendas”.76 Dr Raven from 
Cambridge Enterprise, on the other hand, noted that regional approaches were not always 
successful and cited the “i10 East of England” collaboration, where the universities were 
“so disparate that it did not really work despite the branding”.77
40. Imperial Innovations thought that a sectoral, rather than regional, focus might be more 
beneficial on the grounds that “the approach needed to get a therapeutic drug to market 
is very different from that required to bootstrap a fast-moving small software business 
to market”.78 Professor McMillan similarly stressed that “different technology transfer 
sectors have different exploitation pathways” and recommended that Praxis Unico, the 
professional association for technology transfer, should be supported to explore “whether 
more could be done on good practice differentiated by specific technology sector”.79 A 
sectoral focus on innovation is also apparent in the Industrial Strategy Green Paper.
41. The lack of a ‘one-size-fits-all’ approach to successful technology transfer does not 
preclude the sharing of best practice. We recommend that UK Research and Innovation 
(UKRI) should, once it is established, work with Praxis Unico to develop and share best 
practice in identifying and nurturing opportunities for technology transfer. Guidance 
should be developed with the needs of smaller technology transfer offices in mind and 
take account of regional and sectoral differences.
42. We discuss in Chapter 4 the separate issue of best practice in IP valuation and 
negotiation.
72 Q225. Kingston University, for example, told us that it did not have the throughput to justify developing 
expertise in-house in areas requiring specific legal expertise, such as patenting. See Kingston University 
(MIP0031).
73 Q225; see also Royal Society (MIP0021) para 23
74 See, for example, Cambridge Enterprise (MIP0029) para 32; Wellcome Trust (MIP0028) para 4; University of 
Oxford (MIP0025) para 28; Royal Academy of Engineering (MIP0023) para 4.7; Imperial Innovations (MIP0020) 
para 3.4; Innovate UK (MIP0006) para 20
75 Q10
76 Q10
77 Q13
78 Imperial Innovations Group plc (MIP0020) para 3.1
79 University Knowledge Exchange (KE) Framework: good practice in technology transfer. Report to the UK higher 
education sector and HEFCE by the McMillan group, September 2016, p 7
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Science and Innovation Audits
43. In 2015, the Government announced funding for Science and Innovation Audits 
(SIAs) to identify regional strengths in research, innovation and infrastructure. The 
Minister told us that SIAs are:
a means by which we can map where there is a capacity for excellence in 
parts of the country that might not immediately spring to mind, so that we 
can ensure that areas that can be in a position eventually to make the most 
of public resources get their fair crack at it.80
44. Universities have collaborated with local business groups to produce SIAs. The 
University of Sheffield described how it had worked with a local consortium comprising 
the Sheffield City Region and the “Lancaster area” Local Enterprise Partnership (LEP) to 
focus on the region’s strength in high value manufacturing.81 Similarly, the University 
of Edinburgh was part of a consortium of local businesses, the City of Edinburgh 
Council, Scottish Enterprise and Innovation Centres Scotland “working to maximise the 
opportunities provided by data driven innovation” through its SIA.82
45. The Minister concluded in November 2016 that the SIA process had “brought together 
business, universities, Local Enterprise Partnerships and other collaborators from across 
the private and public sectors”.83 Understanding the UK’s research strengths could also be 
valuable information as the Government launches its Industrial Strategy Challenge Fund 
which looks “to back technologies at all stages where the UK has the potential to take an 
industrial lead”.84
46. Dame Ann Dowling, however, cautioned that SIAs should not be “simply looking 
to see what a local area can do” but that there should be coordination with “other areas 
that have similar strengths rather than setting up a regional competition”.85 Professor 
McMillan was concerned that the SIAs were a “little backward-looking”—and were 
identifying where an area was already strong—”rather than forward-looking”.86 Though 
the SIAs do feature a ‘gap analysis’, the ‘gaps’ identified tend to relate to existing sectors 
and rather than addressing the development of new sectors. The need to look more to the 
future was emphasised by Professor Paul Nightingale from the University of Sussex when 
he gave evidence on the Government’s Industrial Strategy Green Paper. He explained that:
it is very difficult to predict what will be important in the future; 100 years 
ago we said steam engines. We need to support not just the incumbents 
[ … ] We need to be driving innovation and be opening up to disruptive 
change.87
80 Q279
81 University of Sheffield (MIP0024) para 5.8
82 Department for Business, Energy and Industrial Strategy (MIP0011) para 77
83 Department for Business, Energy and Industrial Strategy, Science and Innovation Audits, Wave 1 Summary 
Report, November 2016, p2
84 HM Government, Building Our Industrial Strategy, Green Paper, January 2017, p 30
85 Q266
86 Q265–266
87 Oral evidence taken on 22 February 2017, HC (2016–17) 991, Q21 [Professor Nightingale]
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47. Science and Innovation Audits have focused on mapping the UK’s existing 
scientific strengths. This is valuable information but the Government also needs to 
know where the weaknesses lie, and where innovation and technology transfer are 
being held back. The gap analysis to date has uncovered weaknesses within existing 
sectors, however, rather than identifying where new sectors need to be developed. 
The Government should task UK Research and Innovation (UKRI), once established, 
with identifying where our research and innovation gaps lie, especially where they are 
holding back technology transfer, and consider how these can be addressed.
Local Enterprise Partnerships
48. Local Enterprise Partnerships (LEPs) are collaborations between businesses and local 
authorities that have a mandate to promote local innovation and “deliver local growth”.88 
There are 39 LEPs in England that have, in total, “been awarded £200 million through [the 
Government’s] Growth Deals for innovation projects”.89 Some Growth Deals have directly 
benefitted universities and increased their capacity for technology transfer. The University 
of Oxford told us that through OxLEP’s the Growth Deal it had “invested £750,000 in 
university start-ups and spin-outs to leverage £8.9m of private investment and create 45 
jobs [ … ] in knowledge intensive firms”.90
49. The Dowling Report found, however, that while LEPs have a remit to support 
innovation within their area, performance to date had “been patchy” and “highly 
variable”.91 Though it identified “good examples of local engagement”, it concluded that 
there was a “need to set a clear national direction and provide stronger support to enable 
them to fulfil this role”.92
50. The relationship expected between LEPs and universities currently appears ill-
defined. The guidance provided by the Government to LEPs when drawing up ‘Strategic 
Economic Plans’ in 2013 (which were then used to negotiate ‘Growth Deals’) made no 
reference to collaborating with universities.93 In the written evidence we received, only 
two universities—Sheffield and Oxford—highlighted collaborations with their LEP.94 
The Industrial Strategy Green Paper states that the Government “will work with Local 
Enterprise Partnerships to review their role in delivering local growth and examine how 
we can spread best practice and strengthen them”.95
51. It was noticeable, however, that neither the Green Paper, nor the Government’s 
evidence to this inquiry, referred to the University Enterprise Zones (UEZ), a scheme that 
aimed to:
encourage universities to strengthen their roles as strategic partners in local 
growth and stimulate development of incubator and/or grow on space for 
small businesses.96
88 HM Government, Building Our Industrial Strategy, Green Paper, January 2017, p125
89 Department for Business, Energy and Industrial Strategy (MIP0011) para 29
90 University of Oxford (MIP0025) para 5
91 The Dowling Review of Business-University Research Collaborations, July 2015, p 3 &para 144
92 ibid
93 HM Government, Growth Deals, Initial Guidance for Local Enterprise Partnerships, July 2013
94 University of Oxford (MIP0025) para 5; University of Sheffield (MIP0024) paras 5.7–5.8
95 HM Government, Building Our Industrial Strategy, Green Paper, January 2017, p125
96 Department for Business, Innovation and Skills, University Enterprise Zones Pilot Evaluation, Outline Evaluation 
Plan and Baseline, Produced for BIS by SQW and Cambridge Econometrics, March 2015, p11
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UEZs are currently being piloted in Bradford, Nottingham, Bristol and Liverpool, with 
the Government providing a £15 million capital fund between 2014 and 2017.97 The future 
of the UEZs once the pilot scheme funding ends in 2017 is unclear. Allan Cook, Vice 
President of the Royal Academy of Engineering, told us that it was “a mistake that the 
university enterprise zones [were] not in [the Industrial Strategy Green Paper]” adding 
that it was an “omission” that needed some reflection.98
52. The 39 Local Enterprise Partnerships in England are potentially well placed to 
help connect local businesses and universities. It is therefore disappointing that they 
are currently lacking any firm obligation, or support, to do so. In contrast, the four 
University Enterprise Zones, established with the explicit aim of increasing interaction 
between universities and businesses in particular geographic areas, face an uncertain 
future.
53. The Government should use the opportunity presented by the Industrial Strategy 
to oblige all LEPs to work with their local universities and build on the strengths of the 
university enterprise zones or else reassign a proportion of their funding sufficient to 
roll-out a national university enterprise zones programme.
97 Department for Business, Innovation and Skills, University Enterprise Zones Pilot Evaluation, Outline Evaluation 
Plan and Baseline, Produced for BIS by SQW and Cambridge Econometrics, March 2015
98 Oral evidence taken on 22 February 2017, HC (2016–17) 991, Q60 [Allan Cook]
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4 Finance, funding and support
54. Commercialising research, whether through the licencing of IP to existing companies 
or through setting up new ‘spin-out’ companies, requires investment and support. In 
many cases, such investment needs to be long-term. A study by Columbia University 
found that in cutting edge areas of science (eg machine learning and regenerative 
medicine) universities were “often filing patents that are 10 years or more ahead of industry 
production—hammers waiting for a nail to appear”.99 This chapter considers some of the 
difficulties accessing long-term finance, as well as other support that is essential to foster 
technology transfer.
Access to finance
55. Accessing finance to commercialise research can prove challenging. The 2015 
Innovation Survey, published by the Department of Business, Energy and Industrial 
Strategy in July 2016, found that the ‘availability of finance’ was the most cited factor 
constraining innovation.100 Much of the written evidence we received focused on a lack 
of early stage funding (known as ‘seed’ and ‘proof of concept’ funding) where ideas need 
capital to start turning them into a reality. The Royal Academy of Engineering stressed 
that:
effective and successful research commercialisation requires sufficient and 
appropriate (pre-)seed stage funding, which can help to fund ‘proof-of-
concept’ activities and bridge the ‘valley of death’ between the development 
of a prototype and a product or service that is an investable proposition.101
56. Imperial Innovations told us that proof of concept funding was “not as widely or 
consistently available as it should be”, adding it was something that “must be addressed 
in order to further unlock the potential of TTOs to be transformative agents in the 
commercialisation process”.102 Similarly, Universities UK drew attention to “the long-
standing dearth of early stage, proof of concept funding in the UK”, and suggested that 
the private sector’s “inability to fill this gap” was a “constrain to research translation”.103
57. Anne Glover from Amadeus Capital Partners explained that ‘proof of concept’ 
funding needed “to be readily available very quickly to be effective” and that “more 
funding” would be “welcome”.104 However, it was the absence of a ‘ladder of financing’, 
and a lack of later stage funding, that Ms Glover thought was still proving problematic, 
four years after identifying the same problem to our predecessor Committee:
99 Orin Herskowitz and Brady Butterfield, “Know thyself: how well do you understand your own IP strategy?” 
Intellectual Asset Management, July/August 2016, p10
100 Department of Business, Energy and Industrial Strategy, The UK Innovation Survey 2015 Main report, Innovation 
Analysis, July 2016
101 Royal Academy of Engineering (MIP0023) para 5.1
102 Imperial Innovations Group plc (MIP0020) para 5.3
103 Universities UK (MIP0016) para 11
104 Q174 [Anne Glover]
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The positive [change] is that we have two more steps upwards. The negative 
one is that there is an even greater chasm at the top. The ladder is still 
needed [ … ] We have to find a way to get our capital markets interested in 
technology companies again. There is capital in the UK. It is just not very 
interested in technology, at the top end in the large asset managers.105
58. Mike Conroy from the British Bankers Association highlighted that the funding gap 
was particularly apparent for “fast-growth businesses seeking venture capital of between 
£10 million and £25 million”.106 There was disagreement in the written evidence, however, 
about the availability, and overall suitability, of venture capital finance for technology 
transfer. The University of Sheffield saw problems with the venture capital (VC) model, 
stating that:
It does not incentivise academic participation, as it is a narrow approach to 
the application of research [ … ] The VC model is generally looking to spin-
out or licence early-stage ideas, with a view to making the best financial 
return at the optimum time. One in 50 of the opportunity disclosures looks 
like a venture capital opportunity. One in 10 of these might get funded. One 
in 10 of those might succeed.107
Others suggested that venture capital was unsuitable for particular sectors, such as the 
biosciences. Cambridge Enterprise noted that VC funds typically backed “ideas over the 
short-term and [required] a quick exit” which, it argued, was “not particularly suited to 
bioscience with its long development and regulatory timeframes”.108
59. Several steps have been taken to try to address these problems. The Wellcome Trust 
announced in May 2016 that, as a charity, it would use its “financial independence” and 
its “freedom to take on problems others would find very challenging” to work “earlier 
and later in the translation pathway”.109 A number of universities also highlighted that 
they had established their own ‘in-house’ investment funds known as ‘patient capital’, 
described by the Russell Group as:
‘evergreen’ funds [that] take a much longer investment time horizon than 
traditional venture capital companies as they do not have fixed term 
investment periods. Instead they reinvest any proceeds back into new start-
ups and their existing portfolio of companies to make returns over longer, 
open-ended periods. Investors in patient capital companies are willing 
to forgo an immediate return in anticipation of more substantial returns 
further down the road.110
105 Q157, Q162
106 Q174 [Mike Conroy]
107 The University of Sheffield (MIP0024) para 1.8; see also Mercia Technologies PLC (MIP0002)
108 Cambridge Enterprise (MIP0029) para 8
109 Stephen Caddick, The future of innovation at the Wellcome Trust, 24 May 2016, https://blog.wellcome.
ac.uk/2016/05/24/the-future-of-innovation-at-the-wellcome-trust/ last accessed 2 March 2017
110 Russell Group (MIP0009) para 4.2
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60. Cambridge Enterprise, the TTO of the University of Cambridge, told us that its 
in-house patient capital fund—Cambridge Innovation Capital—and Imperial College’s 
fund—Imperial Innovations—were each:
investing at a rate of around £60m p.a. each in early stage technology 
companies compared with the British Venture Capital Association 
membership which (excluding Imperial Innovations) is only investing 
£48m p.a. across early stage tech and non-tech.111
61. Such funds, however, are not widespread. Anne Glover stated that there were “not 
many investors” that would support patient capital funds and that there was “a limited 
pool in the UK”.112 The Royal Academy of Engineering was concerned that while the 
recent increase in patient capital investment vehicles had “created a welcome market of 
investors for universities to choose from”, the existence of exclusive deals—“whereby the 
investment vehicle has the exclusive right to commercialise all IP from a university”—
can restrict “academic founders [ … ] in the choice of initial investors for a spin-out”.113 
This, in turn, can “mean a spin-out misses out on investment and support that is more 
appropriate for their company”.114
62. The Minister described the development of patient capital by “some of our best-known 
institutions” as “hugely welcome”, noting that “10 years ago this simply did not exist”.115 
Highlighting the Government’s forthcoming review of patient capital, announced in the 
2016 Autumn Statement, the Minister told us that the challenge now was “to ensure that 
these pools of capital become available more broadly across our system”.116 According to 
the Government, the review is to be led by HM Treasury and supported by an industry 
panel drawn from “leading investors and entrepreneurs” and chaired by Sir Damon 
Buffini.117
63. Difficulties accessing long-term finance have been a persistent barrier to 
commercialising the UK’s scientific and technological breakthroughs. A handful of 
UK universities have been at the forefront of developing the ‘patient capital’ model to 
address this funding gap. It is therefore surprising that the terms of reference for the 
Government’s forthcoming Patient Capital Review do not mention universities, nor is 
there any indication that they will have a place on the ‘industry panel’ that will support 
the review.
64. The Government’s Patient Capital Review must engage with the university sector 
and learn from those universities that have developed patient capital schemes.
IP valuation and negotiations
65. Under UK law, notably the Patents Act 1977 and the Copyright, Designs & Patents 
Act 1988, IP generated in the course of a person’s normal employment belongs to the 
111 Cambridge Enterprise (MIP0029) para 17
112 Q187; see also The University of Sheffield (MIP0024) para 1.8
113 Royal Academy of Engineering (MIP0023) paras 5.2–5.4
114 ibid
115 Q283
116 Q283
117 Department for Business, Energy and Industrial Strategy and HM Treasury, Terms of reference for the Patient 
Capital Review, February 2017
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substantive employing organisation.118 Universities typically assert ownership rights 
to intellectual property developed using its resources, so that when efforts are made to 
licence its IP, or spin-out a company around it, the university would usually value the IP. 
Universities tend to take an equity stake in a spin-out company or royalties in licensing 
deals, though practices vary between institutions.
66. Reaching an agreement with academics (and investors) can involve universities in 
complex negotiations A survey undertaken as part of the Dowling Review found that 
negotiations taking “too long to complete”, and processes being “difficult to navigate 
or taking too long”, was the number one barrier to collaboration cited by businesses.119 
There have been suggestions that negotiation delays arise from technology transfer offices 
overvaluing IP in a bid to generate short-term income, or taking a disproportionally large 
equity share, though the evidence we heard did not confirm whether this was common 
practice. The Dowling Review identified a tension between “the desire [for universities] to 
earn short-term income from their IP and the need to deliver wider public benefit, and 
potentially greater long-term return on investment from this IP”.120 Dame Ann explained 
to us that:
technology transfer offices are quite often asked to bring in enough money 
to pay for their running costs. If they do that, they tend to look to shorter-
term licensing than spin-outs, which have a much longer time to grow.121
67. There was mixed evidence on whether the tension set out in the Dowling Review 
reflected the experiences of our other witnesses. The BioIndustry Association (BIA) noted 
that Dame Ann’s findings “[resonated] with many BIA members”122 and the Royal Society 
told us that:
Some academics reported a sense that universities have strategic interest 
in pursuing one avenue for commercialisation over another, in particular 
to prioritise short-term revenue generation to make the TTO financially 
sustainable. This may make TTOs risk averse and is perceived to be a cause 
of the high equity shares and IP valuations that they expect.123
The Wellcome Trust’s research into technology transfer also reported that “a pressure to 
create revenue can lead to overvalued IP, licencing terms that disincentivise deals, and 
insufficient consideration of quality measures”.124
68. The Russell Group of universities, on the other hand, strongly disagreed:
Any suggestion universities and TTOs are focused on short-term returns 
from IP is misleading [ … ] Universities must cover the cost of the research 
they conduct, and it is reasonable to require payments for IP generated from 
118 The legal rules of IP ownership are different for university employees and non-employees such as students, 
consultants, clinicians, honorary academics and employees of other bodies. See Intellectual Property Office, 
Intellectual Asset Management for Universities, June 2014
119 The Dowling Review of Business-University Research Collaborations, July 2015, p 27
120 The Dowling Review of Business-University Research Collaborations, July 2015, p 3
121 Q248
122 BioIndustry Association (MIP0034)
123 The Royal Society (MIP0021) para 16
124 Wellcome Trust, The UK’s innovation ecosystem, Summary of a review commissioned by the Wellcome Trust, not 
dated
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university research in order to support further activities. This is not a form 
of short-term return but a fair and proportionate return on investment for 
the university’s intellectual contribution.125
Similarly, Dr Tony Raven from Cambridge Enterprise, the University of Cambridge’s 
TTO, told us that:
If we [Cambridge Enterprise] were looking for short-term income, we would 
do very different deals. Most of the deals we do are not a typical deal, in that 
we do not ask for big up fronts; we just recover our patent costs [ … ] We are 
not looking to suck out short-term money.126
Universities UK also stressed that technology transfer was generally a cost to universities 
and not a source of revenue.127
69. Other witnesses suggested that the very nature of negotiations, together with the 
challenges posed by valuing new, early-stage technologies, can mean that a degree of delay 
and difficulty is unavoidable. As Mark Anderson from the Law Society explained, “it is 
a negotiation: inevitably, there are going to be difficulties sometimes”.128 Dr Toby Basey-
Fisher shared his experience of spinning out his company, Eva Diagnostics, noting that 
the process was:
always going to be challenging, because it involves many different 
stakeholders with many different views and expectations of what they want 
and what they would like to see happen and those coming together. It will 
be a difficult process.129
70. The Russell Group also highlighted how the:
Valuation of IP assets can [ … ] be extremely challenging due to market 
uncertainty related to early-stage university technologies, including 
timescales to market, investment needs and avenues to achieving 
commercially viable outcomes.130
TTOs tend to manage a “breadth of technologies and disciplines” which the Academy 
of Medical Science thought made it “challenging for TTO staff to acquire the in-depth 
knowledge [ … ] required to fully understand commercialisation opportunities” and 
accurately value them.131 Dr Raven emphasised that this was particularly “difficult and 
challenging for people in the smaller [TTOs]”.132
71. Support and guidance for TTOs appears to be in short supply. According to the 
Royal Academy of Engineering, there are currently “limited materials” available that 
“provide comprehensive guidance on approaches to market assessment and opportunity 
125 Russell Group (MIP0009) para 3.5
126 Q5
127 Universities UK (MIP0016) para 6, see also Praxis Unico (MIP0014) para 22 & Universities Scotland (MIP0030) 
para 8
128 Q201
129 Q82
130 Russell Group (MIP0009) para 3.3
131 Academy of Medical Sciences (MIP0012) para 3
132 Q62 [Dr Raven]
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evaluation”.133 The Intellectual Property Office (IPO) has, however, recently updated its 
Lambert toolkit, which includes a ‘template agreement’ for handling the IP in collaborative 
research.134 The Government reported that:
research commissioned by the IPO revealed that the Lambert toolkit has 
been a very useful resource, reducing legal costs, resources and time in 
negotiating agreements between publicly-funded research organisations 
and industry.135
Cranfield University described the Lambert model agreements as “a highly effective 
example of a toolkit that eases collaborative university-industry engagement”, while other 
universities thought that acceptance and take up of the agreements was relatively low.136
72. In its Industrial Strategy Green Paper, published in January 2017, the Government 
stated that it will:
commission research on different institutions’ principles and practices on 
commercialisation of intellectual property, including how they approach 
licensing intellectual property and take equity in spin-outs [ … ] The 
Government will then use the findings to identify and spread best practice 
among universities’ technology transfer offices.137
73. Technology transfer offices (TTOs) should be focused on taking a long-term 
approach to developing IP. Some, it is claimed, look primarily for short-term revenue, 
though the extent to which this influences TTO practices is unclear. TTOs are often 
situated in the middle of complex IP negotiations, balancing competing priorities, 
with varying degrees of support.
74. We encourage the Government to use its forthcoming research on the 
commercialisation of intellectual property to examine what skills are needed to 
successfully value IP and broker negotiations, as well as how these skills may vary by 
sector. The research should engage with technology transfer offices (TTOs), Innovate 
UK, the research councils, funding councils and sector-specific bodies. The resulting best 
practice guidance must be made available online to TTOs, with consideration given to 
disseminating the material further through training courses and through establishing a 
mentoring scheme.
Higher Education Innovation Funding (HEIF)
75. The Higher Education Funding Council for England’s (HEFCE) Higher Education 
Innovation Fund (HEIF) was repeatedly singled out by universities as an invaluable source 
133 Royal Academy of Engineering (MIP0023) para 4.4
134 The Lambert toolkit aims to assist “academic or research institutions and industrial partners who wish to 
carry out research projects together” through providing template collaboration agreements that set out 
basic principles of collaboration. See https://www.gov.uk/guidance/university-and-business-collaboration-
agreements-lambert-toolkit
135 Department for Business, Energy and Industrial Strategy (MIP0011) para 33; see also Q293
136 Cranfield University (MIP0015) para 6.3; see also Cambridge Enterprise (MIP0029) para 28, Imperial Innovations 
Group plc (MIP0020) para 3.5, Q70 [Dr Clare]
137 HM Government, Building Our Industrial Strategy, Green Paper, January 2017, p32
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of flexible funding that had helped them to develop their technology transfer capabilities.138 
Cambridge Enterprise described HEIF as an “important funding stream for the success of 
technology transfer in the UK” adding that “the ring fencing of the funding for knowledge 
transfer and commercialisation activity is helpful to ensuring a professional and responsive 
service”.139 Welsh Universities, however, highlighted that there was an “absence of HEIF 
type monies in Wales” and that with “little or no funding [ … ] available for TTOs”, 
Swansea University reported that its “commercial throughput [was] severely limited by a 
lack of predictable funding”.140
76. The Minister recognised that HEIF played “a crucial part in helping fund the 
operations of technology transfer offices in our universities” adding that the “additional 
£100 million”, announced at the 2016 Autumn Statement “to fund collaboration between 
universities in support of knowledge exchange activities” would be “either very HEIF-like 
or extremely complementary to HEIF”.141
77. The Higher Education Innovation Fund (HEIF) has played a crucial role in 
enabling universities to develop their technology transfer capabilities. We welcome 
the additional £100 million investment in knowledge exchange activities by the 
Government and its commitment to HEIF-type funding. Such funding should be 
consistently available across the United Kingdom.
Advice and simplifying the innovation landscape
78. Academics have varying experience when it comes to negotiating commercialisation 
deals. Innovate UK found that first-time academic entrepreneurs “frequently confront a 
deal-making process they do not completely understand” and sometimes “do not fully 
recognise how the interests of the TTO and university may diverge from their own”.142 The 
Royal Society suggested that academics, at all career stages, were “likely to need support to 
develop business awareness before they [could] effectively engage with commercialisation 
activities”.143 It singled out “training, network building and mentoring” as important 
aspects of “developing an entrepreneur”.144
79. We heard about several schemes that provide this type of support. Chris Mairs from 
Enterprise First explained that it typically spent:
six months intensively working with the start-up, mentoring them not so 
much on the technology [ … ] but on how to build a business, how to go out 
and raise finance, how to create contracts, how to share data with businesses 
and so on. It is a very full-on process.145
The Royal Academy of Engineering’s Enterprise Fellowships also provide an “intensive 
bespoke package of training and mentoring” delivered by “leading engineers with first-
138 University of Oxford (MIP0025) para 8; Royal Academy of Engineering (MIP0023) para 3.5; The Royal Society 
(MIP0021) para 18; Imperial Innovations Group plc (MIP0020) para 2.3; The Institute of Cancer Research, London 
(MIP0018) para 11; Cranfield University (MIP0015) para 4.1; University College London (MIP0013) para 7
139 Cambridge Enterprise (MIP0029) para 2.5
140 Swansea University (MIP0022)
141 Q287
142 Innovate UK (MIP0006)
143 The Royal Society (MIP0021) para 21
144 ibid
145 Q195
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hand experience of founding, building and leading successful engineering and technology 
companies”.146 When we asked one of its Enterprise Fellows, Dr Toby Basey-Fisher, what 
was more valuable to him—the funding or the mentoring—he replied:
The mentoring [ … ] For us, the biggest requirement has always come from 
having the right individuals who are very knowledgeable in our space to 
guide and help us understand how best to allocate the resource that we have 
been given to achieve the greatest impact for the company as a whole.147
80. Other witnesses emphasised that advice and mentoring were essential to help guide 
businesses and academic entrepreneurs through the complexity of the UK’s innovation 
landscape. As Dr Nelki from the Wellcome Trust explained:
I can understand why an SME, particularly without that mentorship and 
expert advice [ … ] could think, “I am not even sure where to start or 
who I should go to in order to get further financing”. There is a degree of 
complexity.148
81. The “complexity of the policy support mechanisms for research and innovation” 
had been singled out in the 2015 Dowling Review as posing a key “barrier to business 
engagement in collaborative activities, especially for small businesses”.149 It recommended 
that the Government:
should seek to reduce complexity wherever possible and, where simplification 
is not possible, every effort should be made to ensure that the interface 
to businesses and academics seeking support for collaborative R&D is as 
simple as possible.150
82. Dame Ann was positive about the progress made in addressing her recommendation. 
She noted that Innovate UK had done “much to simplify their programmes” and also 
highlighted Innovate UK’s ‘no wrong door policy’:
No matter how a business first approaches them, Innovate UK internally 
will do what we refer to as hide the wiring and make sure that business is 
guided to the right part of Innovate UK seamlessly. That is absolutely a huge 
step forward.151
83. The Royal Academy of Engineering, however, were concerned about the development 
of new finance products by Innovate UK. In the 2015 Spending Review, the Government 
announced that Innovate UK would allocate £165 million of its budget to new finance 
products by 2019–20. Although the precise form that the new finance products will take 
is yet to be decided, they will generally involve a move from grants to loans. We raised 
concerns about this shift in 2015 in our Science Budget report.152 In this inquiry, the Royal 
Academy of Engineering told us that:
146 Royal Academy of Engineering (MIP0023) paras 1.2 & 4.8
147 Q77
148 Q230 [Dr Nelki]
149 The Dowling Review of Business-University Research Collaborations, July 2015, p 2
150 The Dowling Review of Business-University Research Collaborations, July 2015, para 33
151 Q244
152 Science and Technology Committee, First Report of Session 2015–16, The science budget, HC 340, paras 76–78
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Serious concerns exist about whether the new financial products Innovate 
UK are developing will be effective in stimulating and supporting early-stage, 
high-risk and disruptive innovation, or business-university collaboration. 
Furthermore, there are concerns that accepting a loan rather than a grant 
may make a company less attractive to downstream investors.153
84. Felicity Burch from the CBI expressed similar anxieties154 while Richard North from 
Rolls Royce worried that:
loans versus grants would be a big retrograde step [ … ] A loan will be a 
liability on the balance sheet and it would be like any other form of company 
investment: whether the loan is from the Government or from a bank, it is 
capital that we have to pay back. It fundamentally changes the approach to 
investing in what are essentially high-risk, early-stage technologies.155
Dr Will West from the BioIndustry Association, however, thought that there might be a 
place for loans at certain stages of the commercialisation process. He explained that while 
“some of the very early-stage translational work will be difficult to do without funding 
it through grants [ … ] loans could have a role in some of the later-stage translational” 
work.156
85. Witnesses also noted that Innovate UK was “underfunded relative to the rest of 
the science and innovation landscape”.157 Innovate UK will, however, be responsible for 
managing the Industrial Strategy Challenge Fund with the research councils158 and, as 
part of the Industrial Strategy Green Paper, the Government is consulting on “which 
challenge areas” the Fund should “focus on to drive maximum economic impact”.159 At 
the time we concluded our inquiry, no details were available on how the fund will be 
disbursed and whether awards will take the form of grants or loans, and/or if funds will 
need to be matched by private sector investment.
86. Efforts to simplify the innovation landscape are slowly moving in the right 
direction. We remain concerned, however, that while Innovate UK has streamlined its 
funding schemes, the proposed shift away from awarding grants, and towards loans, 
could undermine the progress that has been made to date.
87. We recommend that the majority of the Industrial Strategy Challenge Fund should 
be disbursed in the form of grants. A small proportion of the Fund should be set aside to 
provide support for business training and mentoring, in order to maximise the success 
rate of the awards that are made.
153 Royal Academy of Engineering (MIP0023) para 7.8
154 Q140 [Felicity Burch]
155 Q140 [Richard North]
156 Q140 [Dr West]
157 Q113 [Felicity Burch]; see also Q156
158 HM Treasury, Autumn Statement 2016, Cm 9362, para 3.29. It is a new cross-disciplinary fund to support 
collaborations between business and the UK’s science base.
159 HM Government, Building Our Industrial Strategy, Green Paper, January 2017, p35
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5 Conclusion
88. Our inquiry has highlighted the major issues on the topic of technology transfer, 
but it is clear that we are not the first to do so. Problems in this area, as well as potential 
solutions, have long been identified and understood. Indeed, the evidence base is strong and 
well-developed due, in no small part, to a succession of high-profile, often Government-
sponsored reviews (at least 12 at the last count) reporting over the last 15 years. While 
successive Governments have made sustained efforts to illuminate the obstacles to research 
commercialisation and technology transfer, it is disappointing to see these endeavours tail 
off, and enthusiasm dwindle, when it comes to taking action to address these obstacles.
89. Our key finding is that successes in identifying the challenges associated with 
technology transfer have yet to be matched by progress in tackling the underlying 
problems. Instead, the ‘review culture’ in this field has obscured an ‘implementation 
deficit’ and a sluggish pace of change. The eighteen month delay between Dame Ann 
Dowling publishing her review into Business-University Research Collaborations, and 
the Government formally responding to her recommendations, is symptomatic of this 
inaction.
90. The Government, has recently sent several strong signals—through the 
establishment of UK Research and Innovation (UKRI), the forthcoming Industrial 
Strategy, and the creation of the Industrial Strategy Challenge Fund—that it is serious 
about technology transfer. Together, these three developments present a valuable 
opportunity to break this cycle of reviews, and shift the Government’s focus towards 
taking actions that will help to foster technology transfer. At the same time, the 
Government must be careful not to damage the UK’s pre-eminent position in academic 
research in pursuit of ever-greater commercialisation.
91. Finally, it is important to re-emphasise that the vast majority of innovations do not 
start as discoveries in academic research. While the attention on technology transfer in 
the Industrial Strategy Green Paper is welcome, the Government must not lose sight of the 
UK’s broader innovation landscape. As Professor Nightingale explained:
there is a big world of innovation out there that [the Green Paper] is not 
focusing on, and that needs to be addressed. If we focus only on that small 
bit [university research], we may distort the system and not fund and 
support bits of the UK innovation system that are very successful.160
92. To ensure the current momentum in advancing technology transfer is maintained, 
the Government should task UK Research and Innovation (UKRI) with publishing 
annual progress reports against the recommendations made in Dame Ann Dowling’s 
review. Those reports should highlight what actions have been taken, and how the UK’s 
technology transfer ecosystem is developing.
160 Oral evidence taken on 22 February 2017, HC (2016–17) 991, Q3 [Professor Nightingale]
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Conclusions and recommendations
Stimulating demand for technology transfer
1. Successful technology transfer does not begin and end with universities; business 
also has a vital part to play. Yet, compared to our OECD counterparts, the research 
intensity of UK business is low. Without a healthy commercial demand for R&D, 
the scope for universities to engage more in technology transfer will be limited. 
Responsibility for remedying this problem does not rest solely with the Government, 
but it should be leading the way by creating conditions that are conducive to 
businesses investing more in R&D. To date, however, the Government’s efforts to 
increase technology transfer have been disproportionately targeted at the university, 
rather than business, sector. (Paragraph 15)
2. The lack of progress forces us to reiterate the recommendation made in our 2013 
report, namely for the Government to “create a commercial demand for university 
engagement to which they are already primed to respond”. Facilitating greater 
investment in UK R&D by British business should be a key goal of the Government’s 
Industrial Strategy. (Paragraph 16)
3. We recommend that the Government’s review of R&D tax credits should carefully 
consider how the qualification and claims process for both the SME, and large 
company, schemes could be simplified so that they explicitly support business R&D in 
collaboration with higher education institutions. (Paragraph 21)
4. Government procurement via the Small Business Research Initiative (SBRI) is a 
valuable means through which to stimulate innovation, especially among SMEs. 
The SBRI, however, has consistently underperformed against the Government’s 
own targets and has yet to reach its full potential. We recommend that the current 
review of the SBRI consider what mechanisms could be put in place to encourage 
small businesses to collaborate with research institutions as part of the SBRI scheme. 
(Paragraph 26)
5. We welcome the development of ‘Konfer’ as a straightforward way for businesses 
to identify potential academic collaborators. Algorithms alone, however, will not 
produce productive collaborations: potential ‘matches’ will need to be nurtured 
through supportive human interventions. We recommend that the Government 
works with the National Centre for Universities and Business to publicise the Konfer 
platform. A business engagement team should also be established alongside Konfer 
to work with businesses and help develop the potential partnerships identified by the 
platform. (Paragraph 31)
6. The UK’s exit from the European Union, combined with the Office for Tax 
Simplification’s reviews of the VAT system, present an opportunity to revise VAT 
rules on the income from academic buildings in a way that facilitates greater 
collaboration with business. We encourage the Office for Tax Simplification to 
examine the VAT rules on shared academic buildings with business as part of its 
current VAT review, and consider how they could be revised to enhance collaboration 
opportunities. (Paragraph 35)
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Regional and sectoral differences
7. The lack of a ‘one-size-fits-all’ approach to successful technology transfer does not 
preclude the sharing of best practice. We recommend that UK Research and Innovation 
(UKRI) should, once it is established, work with Praxis Unico to develop and share best 
practice in identifying and nurturing opportunities for technology transfer. Guidance 
should be developed with the needs of smaller technology transfer offices in mind and 
take account of regional and sectoral differences. (Paragraph 41)
8. Science and Innovation Audits have focused on mapping the UK’s existing scientific 
strengths. This is valuable information but the Government also needs to know 
where the weaknesses lie, and where innovation and technology transfer are being 
held back. The gap analysis to date has uncovered weaknesses within existing 
sectors, however, rather than identifying where new sectors need to be developed. 
The Government should task UK Research and Innovation (UKRI), once established, 
with identifying where our research and innovation gaps lie, especially where they 
are holding back technology transfer, and consider how these can be addressed. 
(Paragraph 47)
9. The 39 Local Enterprise Partnerships in England are potentially well placed to 
help connect local businesses and universities. It is therefore disappointing that 
they are currently lacking any firm obligation, or support, to do so. In contrast, the 
four University Enterprise Zones, established with the explicit aim of increasing 
interaction between universities and businesses in particular geographic areas, face 
an uncertain future. (Paragraph 52)
10. The Government should use the opportunity presented by the Industrial Strategy to 
oblige all LEPs to work with their local universities and build on the strengths of the 
university enterprise zones or else reassign a proportion of their funding sufficient to 
roll-out a national university enterprise zones programme. (Paragraph 53)
Finance, funding and support
11. Difficulties accessing long-term finance have been a persistent barrier to 
commercialising the UK’s scientific and technological breakthroughs. A handful of 
UK universities have been at the forefront of developing the ‘patient capital’ model 
to address this funding gap. It is therefore surprising that the terms of reference for 
the Government’s forthcoming Patient Capital Review do not mention universities, 
nor is there any indication that they will have a place on the ‘industry panel’ that 
will support the review. (Paragraph 63)
12. The Government’s Patient Capital Review must engage with the university sector 
and learn from those universities that have developed patient capital schemes. 
(Paragraph 64)
13. Technology transfer offices (TTOs) should be focused on taking a long-term 
approach to developing IP. Some, it is claimed, look primarily for short-term 
revenue, though the extent to which this influences TTO practices is unclear. TTOs 
are often situated in the middle of complex IP negotiations, balancing competing 
priorities, with varying degrees of support. (Paragraph 73)
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14. We encourage the Government to use its forthcoming research on the commercialisation 
of intellectual property to examine what skills are needed to successfully value IP and 
broker negotiations, as well as how these skills may vary by sector. The research should 
engage with technology transfer offices (TTOs), Innovate UK, the research councils, 
funding councils and sector-specific bodies. The resulting best practice guidance 
must be made available online to TTOs, with consideration given to disseminating 
the material further through training courses and through establishing a mentoring 
scheme. (Paragraph 74)
15. The Higher Education Innovation Fund (HEIF) has played a crucial role in 
enabling universities to develop their technology transfer capabilities. We welcome 
the additional £100 million investment in knowledge exchange activities by the 
Government and its commitment to HEIF-type funding. Such funding should be 
consistently available across the United Kingdom. (Paragraph 77)
16. Efforts to simplify the innovation landscape are slowly moving in the right direction. 
We remain concerned, however, that while Innovate UK has streamlined its funding 
schemes, the proposed shift away from awarding grants, and towards loans, could 
undermine the progress that has been made to date. (Paragraph 86)
17. We recommend that the majority of the Industrial Strategy Challenge Fund should be 
disbursed in the form of grants. A small proportion of the Fund should be set aside to 
provide support for business training and mentoring, in order to maximise the success 
rate of the awards that are made. (Paragraph 87)
Conclusion
18. The Government, has recently sent several strong signals—through the 
establishment of UK Research and Innovation (UKRI), the forthcoming Industrial 
Strategy, and the creation of the Industrial Strategy Challenge Fund—that it is 
serious about technology transfer. Together, these three developments present a 
valuable opportunity to break this cycle of reviews, and shift the Government’s 
focus towards taking actions that will help to foster technology transfer. At the same 
time, the Government must be careful not to damage the UK’s pre-eminent position 
in academic research in pursuit of ever-greater commercialisation. (Paragraph 90)
19. To ensure the current momentum in advancing technology transfer is maintained, 
the Government should task UK Research and Innovation (UKRI) with publishing 
annual progress reports against the recommendations made in Dame Ann Dowling’s 
review. Those reports should highlight what actions have been taken, and how the 
UK’s technology transfer ecosystem is developing. (Paragraph 92)
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Annex: Graphene research and 
innovation
1. In March 2016, members of the Committee161 visited the National Graphene Institute 
(NGI) at the University of Manchester, the national centre for graphene research in the 
UK, which was officially opened by the then Chancellor of the Exchequer in March 2015. 
Graphene, a one atom thick form of carbon, has great but still uncharted potential—it is 
one hundred times stronger than steel and conducts electricity better than copper. We 
discussed the NGI’s work with the University of Manchester vice-chancellor and others 
and saw the NGI laboratories.
2. In March 2016 media reports appeared which alleged that some academics had 
concerns about the NGI’s safeguards on its research and that its intellectual property was 
being inappropriately used by a company with Taiwanese links (though UK-registered)—
BGT Materials—and Chinese universities.162
3. We decided to examine the state of research and innovation of graphene, as well as 
the media allegations about the University’s intellectual property management. We took 
oral evidence from Sir Andre Geim, one of the discoverers of graphene, the University, 
businesses involved in commercialising graphene, Innovate UK and Baroness Neville-
Rolfe, then minister for intellectual property.163 We also received written evidence from 
these witnesses and from others.164
Graphene research and its commercialisation
4. The University of Manchester highlighted the extent of the likely growth in the global 
market for ‘graphene materials’—from $20 million in 2014 to more than $390 million in 
2024, and “much higher” for ‘graphene-enabled products’.165 Sir Andre Geim described 
graphene as “a revolution in terms of new materials”, and explained that “the superlatives 
that the material has attracted—the strongest, the thinnest, the most conductive, the most 
pliable and so on—definitely indicate that there are many possibilities”.166
5. Sir Andre emphasised, however, that graphene’s development was still at a relatively 
early stage:
What we are witnessing now is the first stage of the commercialisation 
of graphene. It is probably less than five years since it was demonstrated 
that this group of materials could be obtained in tonnes and in square 
kilometres. [ … ] At the moment all applications are, frankly speaking, 
simple, dirty and marginal improvements, not the killer applications that 
everyone is talking about. This is the natural progression. Take the silicon 
age. It took between 20 and 40 years to study the properties of silicon in 
161 Victoria Borwick MP, Stella Creasy MP and Graham Stringer MP.
162 Academics in revolt as China reaps benefits of British breakthrough’, Sunday Times, 13 March 2016
163 Oral evidence taken on 26 April 2016, HC (2015–16) 960, and on 13 September 2016, HC (2016–17) 159
164 Science and Technology Committee, Graphene inquiry (references to the inquiry’s written evidence are labelled 
with a ‘GRA’ prefix).
165 University of Manchester (GRA0012); IDTechEx, Graphene Markets, Technologies and Opportunities 2014–2024 
(May 2014)
166 Oral evidence taken on 26 April 2016, HC (2015–16) 960, Q63
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terms of fundamental research and applications. Then some very obscure 
applications came about, first ugly transistors, then simplistic circuits and 
so on. It took 50 to 60 years before we got our shiny iPhones.167
6. That shaped the role of the University in facilitating graphene’s development. Sir 
Andre Geim told us:
I see the relationship between the University and collaborating companies 
as a way to stimulate graphene developments for the good of UK plc rather 
than for profit. If and when the companies start generating profits, the 
University will of course benefit through shareholding and patents. But this 
is secondary. [ … ] I only wish someone would use our IP or patents, but 
it is still too early at this stage of graphene development. The Institute’s 
involvement has been to provide expertise in graphene, which allows 
companies including BGT Materials to avoid silly mistakes. [ … ] This is 
the Institute’s most important function for the moment.168
7. The Government has invested more than £120 million “in graphene research, 
training and development”.169 Last month it announced further funding grants for the Sir 
Henry Royce Institute for Advanced Materials at Manchester, which undertakes graphene 
research.170
8. The University of Manchester told us that it had “a strategy of pursuing strategic 
partnerships, promoting inter-disciplinarity and understanding partners’ needs” and 
that:
This has been reflected in our approach to graphene where partnerships may 
be strategic or on a project basis. There are three kinds of projects: Those 
which are completely new [ … ], those which rely on existing industry with 
a strong presence in the UK [ … ] and those which rely on existing industry 
which does not have a strong presence in the UK.171
9. Some of our witness were uncertain about the NGI’s role. Tim Harper thought it 
was unclear whether its role was “purely for academic research or whether it is supposed 
to also lead to the commercialisation of graphene”172. He thought the line between the 
two was “fuzzy”.173 Others—Ray Gibbs of Haydale Graphene Industries, Dr Liam Britnell 
from BGT Materials and Harry Swan of Thomas Swan & Company—did not share that 
uncertainty.174
10. The NGI’s focus, the University of Manchester told us, was on “academic-led research 
(‘Technology Readiness Levels’ 1–5) into graphene/related 2-D materials in collaboration 
with industry”. Its work involved the “demonstration of new concepts, new applications 
and fundamental studies, and establishing the potential of graphene by producing new 
167 Oral evidence taken on 26 April 2016, HC (2015–16) 960, Q63
168 ‘Sir Andre Geim: response to Sunday Times’, Manchester university website, 16 March 2016
169 BIS (GRA020); Oral evidence taken on 26 April 2016, HC (2015–16) 960, Q64
170 HM Government, ‘£229 million of industrial strategy investment in science, research and innovation’, Gov.uk 
press release (23 February 2017)
171 University of Manchester (GRA0012)
172 Tim Harper (GRA0006)
173 Oral evidence taken on 26 April 2016, HC (2015–16) 960, Qq24–25
174 Oral evidence taken on 26 April 2016, HC (2015–16) 960, Qq25–27
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concept products and processes”.175 The Centre for Process Innovation, part of the High 
Value Manufacturing Catapult, believed that the UK spent more on graphene research 
than on application and manufacturing. They told us that “it may be that competitors are 
deploying more of their resources on the exploitation of graphene technology”.176
11. The Graphene Engineering Innovation Centre, due to open in 2018, is designed to help 
such technology exploitation. The University of Manchester explained that while the NGI 
was under construction it became evident that “its effectiveness would be substantially 
enhanced by creating a further institution to [ … ] provide convincing demonstrations 
of next-generation products and processes in a way that de-risked them for industry.” 
This, they told us, “underpinned the rationale for setting up the Graphene Engineering 
Innovation Centre”, which will focus on industry led technology development (Technology 
Readiness Levels 3–6).177 Professor Luke Georghiou, Vice-President for Research and 
Innovation at the University of Manchester, also explained that the NGI (unlike the 
Graphene Engineering Innovation Centre) was “a research place” and therefore not liable 
to VAT.178
Access for SMEs
12. One of the issues raised in the media reports last year was that SMEs were finding it 
difficult to get access to the NGI. Dr Nigel Salter of 2-D Tech, a graphene SME, told us that 
his company’s relationship with the University was “generally poor: There was a culture of 
competition and mutual distrust between the University academics and 2-D Tech”.179 He 
wanted to see universities adopting longer term strategies for sharing intellectual property 
with SMEs:
Universities tend to aim to establish a portfolio of patents that they then 
endeavour to licence for short-term return or use as a basis for spin-out 
companies. Both of these routes tend to preclude the possibility of working 
with existing SMEs who can take on the seed-stage ideas and provide a 
commercial platform. Universities should consider the option of retaining 
ownership of patents, but giving access to SMEs to develop the technology 
and accepting that any returns may be many years away. [ … ] In the current 
febrile world of graphene patents, there is much to be said for universities 
holding ownership, providing they adopt practical and long term strategies 
for sharing with SMEs, many of whom will not persist.180
13. Dr Erik Cox and his company, Inclusive Designs Ltd, complained that the NGI 
resisted meeting them, citing “possible confidentiality issues with other projects”.181 Tim 
Harper, a nanotechnology entrepreneur, similarly criticised the NGI for “choosing to 
partner chiefly with large multinational corporations”.182 Some SMEs complained that 
fees charged by the University for exploratory engagement presented a problem for them.183
175 University of Manchester (GRA0012)
176 Centre for Process Innovation (GRA0008)
177 University of Manchester (GRA0012)
178 Oral evidence taken on 26 April 2016, HC (2015–16) 960, Q91
179 Dr Nigel Salter (GRA0011)
180 Dr Nigel Salter (GRA0011)
181 Inclusive Designs Ltd (GRA0005); Oral evidence taken on 26 April 2016, HC (2015–16) 960, Qq4, 9, 20
182 Tim Harper (GRA0006); Oral evidence taken on 26 April 2016, HC (2015–16) 960, Q20
183 Oral evidence taken on 26 April 2016, HC (2015–16) 960, Qq61–62
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14. Others were positive about their relationship with the NGI and the University, 
including three of our witnesses—Ray Gibbs (Haydale Graphene Industries),184 Dr Liam 
Britnell (BGT Materials)185 and Harry Swan (Thomas Swan & Company).186
15. Innovate UK emphasised that “most UK SMEs are focused on ‘up stream’ processes 
for graphene related technology; that is, manufacture of graphene itself, or intermediate 
products such as inks and composites, rather than final end-products such as light bulbs 
or structural composites.187 The University of Manchester disputed the complaints we 
had received from some SMEs.188 They told us that it was working on graphene with 69 
organisations (associated with 85 projects), of which 28 were SMEs (including 20 SMEs 
with a UK manufacturing base).189 They explained how their links with different types of 
businesses depended on the stage of maturity of the relevant technology:
Our approach is to enter into non-exclusive arrangements to optimise 
opportunities for collaboration and commercial returns. IP is made 
available on appropriate terms to secure collaborative arrangements with 
business for the NGI, given that our strategy envisaged that ‘first’ significant 
commercialisation is likely to be achieved through such engagement with 
established companies [ … ]. ‘Second’ and ‘third’ phases will be achieved 
through our own spin-outs led by respected entrepreneurs and engineering-
savvy CEOs, and student start-ups, and then ultimately licensing activities. 
This would be expected at the point when the market (for angel and venture 
capital investment and stand-alone licensing) begins to mature.190
16. The University told us that it had ‘project partners’ which included major global 
companies as well as “several SMEs”. It also had two ‘strategic partners’—Morgan Advanced 
Materials and BGT Materials—which brought “the kind of product engineering and 
design expertise necessary for commercialising 2D materials, which is in short supply in 
the UK”.191 Professor Georghiou explained that “we find it easier to work with established 
companies. That is not necessarily a statement about size; we include SMEs in the term 
“established companies”, but they have to have a sufficiently developed infrastructure and 
employ people who are able to use the relevant science”, and that the University required 
payment for its substantive contacts with businesses because of a universities-wide 
requirement to “work at cost”.192
IP management and patents
17. Worldwide, the number of graphene-related patent applications rose to over 9,000 
in 2014 from 1,000 in 2010, according to the UK Intellectual Property Office, with most 
184 Oral evidence taken on 26 April 2016, HC (2015–16) 960, Q8
185 Oral evidence taken on 26 April 2016, HC (2015–16) 960, Qq8, 16
186 Oral evidence taken on 26 April 2016, HC (2015–16) 960, Q18
187 Innovate UK (GRA0015)
188 A group of SMEs raised concerns, and the University of Manchester responded, in successive submissions: Tim 
Harper (GRA022), University of Manchester (GRA0026), Manchester Graphene Technologies Ltd (GRA0027), 
University of Manchester (MIP0027), Brian McCann, Tim Harper and Alex Stewart (MIP0033), and University of 
Manchester (MIP0035).
189 Oral evidence taken on 26 April 2016, HC (2015–16) 960, Q66; University of Manchester (GRA0012) updated by 
(MIP0035)
190 University of Manchester (GRA0012
191 University of Manchester (GRA0012)
192 Oral evidence taken on 26 April 2016, HC (2015–16) 960, Q75
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submitted by China. The Centre for Process Innovation, part of High Value Manufacturing 
Catapult, noted that in some countries there is a culture that promotes the filing of patent 
applications, but that many of these would never be granted. The Centre for Process 
Innovation highlighted that producers and users of new materials, such as graphene, 
develop intellectual property through the accumulation of know-how, and that “in many 
early-stage organisations [ … ] retaining internal know-how is often of greater value than 
patents”.193
18. Innovate UK explained the limitations of patenting and of the number of patents as 
a measure of innovation:
There are numerous approaches to the commercialisation of intellectual 
property, from practising in secret at one end, to patent filing to establish 
a monopoly position at the other. Companies often combine different 
approaches and patents are also filed to put the innovation into the public 
domain to prevent someone else from making a claim to that particular 
invention. It is important to understand that a patent is a small part of the 
commercialisation process. On their own patents generate relatively little 
value. [ … ] Simply counting the number of patents produced within a 
region or country is a poor measure of innovation, especially with some 
companies engaged in ‘patent thicket’ strategies.194
19. In a similar vein, Dr Nigel Salter, the managing director of 2-D Tech, a graphene 
SME, told us:
Patents come in many flavours and some are worth more than others. The 
objective should be to identify a market and a technological solution and then 
protect this combination … Of themselves, many early-stage conceptual 
patents have little worth, and can become barriers to partnerships, shared 
endeavour and meaningful communication. They are important, but are 
a means to an end and not an end in themselves. [ … ] In the graphene 
world there is a tendency to patent at a very early stage and well before the 
scope, the value and the technology is suitably mature. [ … ] Researchers 
are keen to patent their ideas, often for personal reputational reasons, and 
to keep the know-how to themselves. This inhibits critical review from an 
application or market perspective. It also wastes time and money and can 
inhibit effective commercialisation.195
20. Dr Nigel Salter, the managing director of 2-D Tech, was concerned about academic 
staff being directors of BGT Materials because, he believed, it “inhibited open discussion 
[ … ] with other companies”.196 The University of Manchester signed a research 
collaboration agreement with BGT Materials—one of the NGI’s two ‘strategic partners’ 
(Annex, paragraph 16)—in October 2013 and has a 17.5% shareholding in the company. 
Professor Georghiou emphasised that “it is absolutely the norm: We have a number of 
academics who sit on the board, never in an executive position”.197 He explained that “if 
193 Centre for Process Innovation (GRA0008)
194 Innovate UK (GRA0015)
195 Dr Nigel Salter (GRA0011); See also Oral evidence taken on 26 April 2016, HC (2015–16) 960, Q46 [Dr Erik Cox] 
and Q54 [Ray Gibbs]
196 Dr Nigel Salter (GRA0011)
197 Oral evidence taken on 26 April 2016, HC (2015–16) 960, Q87
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there is a partnership with a business in a particular area and our researchers are working 
with one company, we cannot then work with another company in an area very close to 
that: It would not matter if the incumbent was a large firm or a small firm.”198
21. BGT Materials similarly refuted last year’s media reports (Annex, paragraph 2) 
alleging that it enjoyed inappropriately favoured access to graphene intellectual property 
or that confidential information was being shared with Chinese universities and 
businesses. BGT Materials told us that non-disclosure agreements had been “respected”.199 
The University of Manchester refuted the claims about academics “boycotting” the NGI 
and insisted that there was no evidence of BGT Materials having access to confidential 
research programmes or of poor safeguards on the University’s intellectual property. Sir 
Andre Geim described the allegations as “ridiculous”.200
22. Professor Georghiou explained that the University developed intellectual property in 
collaboration with companies, which would have “the full rights, usually by their sector”, 
but that the University would retain the right to use it in further research and to apply it 
in other sectors.201 When it came to graphene, the University explained that:
The initial method of isolating graphene could not sensibly be patented 
as this was not a commercial process and applications were not then 
known. The sole effect at that time would have been to restrict others from 
experimenting on the material, which is counter to the University’s ethos. 
[ … ] The number of patents filed or published has been cited as a measure 
of research and commercial activity, but numbers do not equate to quality 
or practically useful inventions. [ … ] Our aim is to acquire ‘enabling’ IP so 
that it provides a broad platform for application and product opportunities 
for ourselves and our collaborators, as well as potentially giving us a position 
which will require others to seek licences from the University to operate 
their IP.202
23. Sir Andre Geim believed that “some academics publish too many patents”. He 
explained that the cost of supporting, or defending, patents had to be taken into account:
I have 10 patents or so at the moment for very specific applications that are 
defensible [ … ] You have to think about the cost of patents. Each patent 
costs £50,000 to support over its lifetime [ … ] Patents are a very inaccurate 
and artificial measure of success [ … ] We are not behind; we are more 
selective in publishing [ … ] If you asked me how many of those 10 patents I 
should have had, I would probably say three or four. I doubt that six of those 
are really going to play anyway [ … ] Patents are a defensive mechanism to 
defend your commercial product. Universities by definition do not produce 
commercial products.203
198 Oral evidence taken on 26 April 2016, HC (2015–16) 960, Q76
199 Oral evidence taken on 26 April 2016, HC (2015–16) 960, Qq29–31, 33–34, 36, 39
200 Oral evidence taken on 26 April 2016, HC (2015–16) 960, Q69
201 Oral evidence taken on 26 April 2016, HC (2015–16) 960, Q96
202 University of Manchester (GRA0012)
203 Oral evidence taken on 26 April 2016, HC (2015–16) 960, Qq101–102
40  Managing intellectual property and technology transfer 
The University of Manchester’s projections were that over the next five years the cost of 
securing and defending its patents in ‘graphene/2-D’ materials would be £750,000 a year.204 
They told us that:
As collaborations and general activity increases, when the NGI comes fully 
online, patent and related costs will likely go higher. These costs have been 
met from our own resources and from our Higher Education Innovation 
Fund allocation.205
Tim Harper, a nanotechnology entrepreneur, believed that “most [university] Technology 
Transfer Offices struggle to cover the costs of evaluating, protecting and licencing 
intellectual property”.206
24. The University told us that it had had an external review of its “graphene activities and 
arrangements” in 2012 which had “supported our approach”. Subsequently, they told us, 
“an independent audit of our graphene IP strategy and practice, led by the then President 
of the Chartered Patent Agents’ Society, in June 2014 fully endorsed our practices with 
some recommendations for improvements”.207
Standards
25. As an evolving technology, the issue of what constitutes graphene has become more 
important. Innovate UK pointed out that “there is no ‘standard’ form of graphene and 
the end product varies from company to company”.208 Innovate UK highlighted that 
“characterising the material requires specialist equipment that is usually out of reach for 
small companies” and that as a result there was some evidence that “variability in the 
quality of graphene supplied from sources (particularly outside the UK) is affecting the 
development of high performance downstream products”.209 Xefro Club, which represents 
a group of dissatisfied customers of a business selling ‘graphene radiators’, told of about 
their dangerous experiences.210 The Financial Conduct Authority has warned about 
scams where consumers are targeted by companies offering unregulated investments in 
graphene.211
26. As Professor Georghiou of University of Manchester put it, “you need standards to 
eliminate [ … ] the bottom-feeders who pretend they have graphene when they do not”.212 
The University emphasised that:
The commercialisation of graphene [ … ] requires a fit-for-purpose 
standards regime. Measurement standards are needed to allow the accurate, 
precise and rapid characterisation of these new materials, and hence assess 
any safety issues. Without them, market confidence is undermined, as users 
cannot compare different commercial materials or develop application 
areas without first understanding how changes in their material ultimately 
204 Oral evidence taken on 26 April 2016, HC (2015–16) 960, Q105; University of Manchester (GRA0012)
205 University of Manchester (GRA0012)
206 Tim Harper (GRA0006)
207 University of Manchester (GRA0012)
208 Innovate UK (GRA0015); See also oral evidence taken on 26 April 2016, HC (2015–16) 960, Q55
209 Innovate UK (GRA0015)
210 Xefro Club (GRA0019). See also response Tim Harper (GRA0023).
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affects their product. The market needs to ‘trust’ what it is getting. […] 
To address this deficit, the NGI and the National Physical Laboratory 
[…] are addressing the perceived metrology and standardisation gap in 
commercialisation.213
Wider issues
27. Our visit to the NGI and our short inquiry on graphene highlighted wider issues 
about the way universities more generally manage the intellectual property of their 
research programmes and engage in technology transfer. In July 2016 we launched such a 
wider inquiry. This Annex, describing our graphene scrutiny, forms part of the report on 
that inquiry.
213 University of Manchester (GRA0012), paras 15, 22–23; National Physical Laboratory (GRA0007)
42  Managing intellectual property and technology transfer 
Formal Minutes
Wednesday 8 March 2017
Members present:
Stephen Metcalfe, in the Chair
Victoria Borwick
Dr Tania Mathias
Derek Thomas
Matt Warman
Draft Report (Managing intellectual property and technology transfer), proposed by the 
Chair, brought up and read.
Ordered, That the draft Report be read a second time, paragraph by paragraph.
Paragraphs 1 to 92 read and agreed to.
Annex and Summary agreed to.
Resolved, That the Report be the Tenth Report of the Committee to the House.
Ordered, That the Chair make the Report to the House.
Ordered, That embargoed copies of the Report be made available, in accordance with the 
provisions of Standing Order No. 134.
[Adjourned till Wednesday 15 March at 9.30 am
43 Managing intellectual property and technology transfer 
Witnesses
The following witnesses gave evidence. Transcripts can be viewed on the inquiry publications 
page of the Committee’s website.
Wednesday 2 November 2016 Question number
Dr Tony Raven, Chief Executive, Cambridge Enterprise, Nick Sturge, 
Director, Engine Shed, University of Bristol, and Dr Claire Brady, Head of 
Technology Transfer, Edinburgh Research and Innovation, The University of 
Edinburgh Q1–67
Dr Phil Clare, Chair, Advocacy Committee, PraxisUnico, Dr Rosa Fernández, 
Research Director, National Centre for Universities and Business, and Dr 
Toby Basey-Fisher, Chief Executive, Eva Diagnostics Q68–110
Tuesday 22 November 2016
Dr Will West, Executive Chairman, CellCentric and Member, BioIndustry 
Association Board, Felicity Burch, Head of Innovation and Digital, CBI, and 
Richard North, Head of IP Protection Licensing and Control, Rolls-Royce Q111–154
Anne Glover, Co-founder and Chief Executive, Amadeus Capital Partners 
Ltd, Chris Mairs CBE FREng, Venture Partner, Entrepreneur First, and 
Mike Conroy, Executive Director, Corporate and Commercial Banking, 
British Bankers’ Association Q155–198
Wednesday 14 December 2016
Mark Anderson, The Law Society IP Law Committee, and Dr Daniel Nelki, 
Science to Health Lead, Wellcome Trust Q199–241
Professor Dame Ann Dowling, President, Royal Academy of Engineering, and 
Professor Trevor McMillan, Vice-Chancellor, Keele University Q242–272
Wednesday 11 January 2017
Jo Johnson MP, Minister of State for Universities, Science, Research and 
Innovation, Department for Business, Energy and Industrial Strategy, 
Jenny Dibden, Director of Science and Research, Department for Business, 
Energy and Industrial Strategy, and Sean Dennehey, Acting Chief Executive 
Officer, Intellectual Property Office Q273–323
44  Managing intellectual property and technology transfer 
Published written evidence
The following written evidence was received and can be viewed on the inquiry publications 
page of the Committee’s website.
MIP numbers are generated by the evidence processing system and so may not be complete.
1 Academy of Medical Sciences (MIP0012)
2 BioIndustry Association (BIA) (MIP0034)
3 Brian McCann, Tim Harper, and Alex Stewart (MIP0033)
4 Cambridge Enterprise (MIP0029)
5 Cardiff University (MIP0010)
6 Cranfield University (MIP0015)
7 Department for Business, Energy and Industrial Strategy (MIP0011) and (MIP0040)
8 Dr Richard Worswick (MIP0008)
9 Higher Education Funding Council (HEFCE) (MIP0007)
10 Imperial College London (MIP0017)
11 Imperial Innovations Group plc (MIP0020)
12 Innovate UK (MIP0006)
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14 inventtory Limited (MIP0039)
15 Kingston University (MIP0031)
16 Mercia Technologies PLC (MIP0002)
17 National Centre for Universities and Business (MIP0019)
18 PraxisUnico (MIP0014)
19 Professor Trevor McMillan (MIP0005) and (MIP0038)
20 Research Councils UK (MIP0026) and (MIP0037)
21 Royal Academy of Engineering (MIP0023)
22 Russell Group (MIP0009)
23 Swansea University (MIP0022)
24 The Institute of Cancer Research, London (MIP0018)
25 The Royal Society (MIP0021)
26 The University of Birmingham (MIP0001)
27 The University of Sheffield (MIP0024)
28 Universities Allied for Essential Medicines (MIP0004)
29 Universities Scotland (MIP0030)
30 Universities UK (MIP0016)
31 University Alliance (MIP0036)
32 University College London (MIP0013)
33 University of Manchester (MIP0027) and (MIP0035)
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34 University of Oxford (MIP0025)
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